Kyverna Therapeutics (NASDAQ:KYTX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Kyverna Therapeutics (NASDAQ:KYTX) from a hold rating to a sell rating in a report released on Saturday morning.

Several other equities research analysts have also issued reports on KYTX. Wells Fargo & Company raised their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Morgan Stanley set a $33.00 target price on Kyverna Therapeutics in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright increased their price target on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Stock Down 6.7%

KYTX stock opened at $8.77 on Friday. The firm has a market cap of $384.13 million, a PE ratio of -2.35 and a beta of 3.45. The business has a 50 day moving average of $7.81 and a 200-day moving average of $5.60. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.12. On average, research analysts expect that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, CTO Karen Marie Walker sold 23,998 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the completion of the transaction, the chief technology officer directly owned 22,636 shares in the company, valued at approximately $276,159.20. This trade represents a 51.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average price of $7.50 per share, with a total value of $999,997.50. Following the completion of the transaction, the insider directly owned 869,317 shares of the company’s stock, valued at $6,519,877.50. This trade represents a 18.12% increase in their position. The SEC filing for this purchase provides additional information. 22.00% of the stock is owned by corporate insiders.

Institutional Trading of Kyverna Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new position in Kyverna Therapeutics in the 3rd quarter valued at $28,000. Phoenix Wealth Advisors purchased a new stake in shares of Kyverna Therapeutics in the second quarter worth $32,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Kyverna Therapeutics in the 2nd quarter valued at about $37,000. Qube Research & Technologies Ltd bought a new stake in shares of Kyverna Therapeutics during the 2nd quarter valued at about $43,000. Finally, Ethic Inc. purchased a new position in shares of Kyverna Therapeutics during the second quarter worth about $56,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.